Top Picks for 2019
Emergent BioSolutions (EBS)
Q3:18 revenues rise 16% YOY. Transaction costs for PaxVax and Adapt Pharma cause cut in guidance for FY:18 EPS, but these accretive deals push FY:19 revenues above $1 billion. We reduce rating to Buy/Long Term and raise our EBS price target from $60 to $70.
Company Description
Emergent BioSolutions is a global specialty life sciences company that develops and commercializes vaccines, drugs, and devices that address biodefense threats. The company is a preferred provider of biodefense products and services to the U.S.